Bli medlem
Bli medlem

Du är här




Significant Significant events after the quarter
events in Q3

  • The · The Extraordinary General Meeting on 18 October resolved

Chinese and US to approve an incentive program for CEO Claus Egstrand through
patent offices an employee option plan, a directed issue of warrants and a
gave advance transfer of warrants.
notice of
their · On 2 November 2021, the Board of Directors decided on
intention to financial targets for the company. Net sales should in 2026
grant patents amount to at least 600 million SEK with an EBIT margin of at
for China and least 28 %.
the US,
for the cod
enzyme that is
one of the key
components of

  • Claus

assumed his
role as CEO on
9 September
2021, about
three months
earlier than
planned, after
he was able to
end prior
ahead of time.
returned to
her previous
role as CFO
and was
appointed to
serve as
Deputy CEO.
Q3 January-September

  • Net sales · Net sales reached SEK 38.5 (69.0) million.

reached SEK · The result for the period was SEK -34.6 million (-12.9).
15.4 (28.3) · Earnings per share, basic and diluted, were SEK -0.24
million. (-0.09).

  • The result · Cash flow from operating activities for the period totaled

for the period SEK -29.3 (-2.4) million.
was SEK -6.1 · Net debt totaled SEK -35.7 (-18.8) million.
million (

  • Earnings

per share,
basic and
diluted, were
SEK -0.04

  • Cash flow

from operating
activities for
the period
totaled SEK
-16.2 (3.4)

Comment from CEO Claus Egstrand:
"Although the times have been challenging for Enzymatica, we look optimistically into the future. We have a fantastic product, strong and experienced partners, and we are convinced that protection against viruses is of great interest to consumers following the pandemic. As for the overall development in Q3 2021, we saw the incidence of colds and the flu returning toward normal levels, along with promising sales trends in new markets such as Poland and Romania. However, we anticipate a lag of up to 6 months in our sales to partners. There are many positive signs, and we expect that the cold/flu market will continue to recover in Q4/2021 and Q1/2022. It is always hard to know what the future holds, but we are cautiously optimistic that we will see good growth in our sales in 2022, compared with 2021."

(SEK MILLION) Q3 Q3 Jan.-Sept. 2021 Jan.-Sept. 2020 Full year

2021 2020 2020
Net sales 15.4 28.3 38.5 69.0 111.2
Gross margin, % 64 74 54 72 68
Operating -6.0 -2.2 -34.7 -13.9 -12.1
Cash flow from -16.2 3.4 -29.3 -2.4 -10.7
Net debt -35.7 -18.8 -9.2
Average number of 24 18 24 18 18

The full interim report is available on

This information is information that Enzymatica is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out below, at 08:50 a.m. CET on 2 November 2021.

FOR more information, please Contact:

Claus Egstrand, Chief Executive Officer, Enzymatica AB
Phone: +44 7780 22 8385 | Email:

Stefan Olsson, Kommunikationschef, Enzymatica AB
Phone: +46 (0) 708 55 11 85 | Email:


Enzymatica AB is a life science company that develops and sells health products mainly to treat upper respiratory diseases and symptoms. The products are based on a barrier technology that includes marine enzymes that includes marine enzymes with unique properties. The company's first product is the medical device product ColdZyme®,a mouth spray for colds. The product has been launched in about 30 markets on three continents. The strategy is to continue to grow by developing more health products, strengthening the company's position in existing markets and expanding into new geographic markets through established partners. The company is headquartered in Lund and is listed on Nasdaq First North Growth Market. For more information, please visit Enzymatica's certified adviser is Erik Penser Bank,+46 (0)8 463 83 00,

Författare Cision